



Foundation Inspire2Live

Annual Report 2023

This report has been approved by the Supervisory Board on April 9th, 2024

Version: March 28, 2024

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Supervisory board report

Inspire2Live has seen significant growth and broadening of scope in 2023, both in the Patient Advocacy and World Campus networks and in the development and execution of concrete projects.

The World Campus has grown to 90 Patient Advocates and more than 40 countries. The monthly online meetings and the Annual Congress are both very energetic and positive events. The quality and efforts of many Patient Advocates make Inspire2Live less dependent on a very limited number of key-figures, something that has been a worry of the Supervisory Board for a long time.

The activation of a daughter company (SanInfo) has greatly increased the execution power of Inspire2Live and creates the possibility to acquire funding not just from donations but also from external investors. A good example is the initiative to bring Multi Cancer Early Detection (MCED) within reach of Low- and Middle-Income countries. First results are actual availability in Bulgaria and Poland, preparations are underway in Romania, Ghana, Kenya, Nigeria and first steps are being considered in several other countries.

The by-laws of Inspire2Live have been adapted so that now there is a governing team of three persons who decide together.

These changes in the organisation have consequences for the role of the Supervisory Board and for the competencies required. Two new members, Marcel Kerkhoven and Rob Agelink have joined the board and Professor Bert Kersten has left the board after being involved in Inspire2Live from the very beginning. We thank him for his long and dedicated service.

During 2023 the board has devoted much attention and discussion to the vision on Supervision in the changing set-up of Inspire2Live. The search for extra members is still ongoing.

Here the bios and photos of the members of the [supervisory board](#).

Amsterdam, March 28, 2024

Sylvia Butzke

Chairman of the Supervisory Board

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Executive board report

This board report contains information about our financial year 2023.

Since February 15th, 2023, Inspire2Live has an executive board, which is formed by Ilona Schelle, Peter Kapitein and Tielo Jongmans. This board manages the daily operations.

Inspire2Live is a not-for-profit organisation that relies heavily upon donations. Read [here](#) about some of our donations and spending.

Here the bios and photos of the members of the [executive board](#), as well as the members of [supportive teams](#).

Our patient advocates

Our organisation now consists of more than 90 active patient advocates in more than 40 countries. We are still expanding. Of course, this is mainly a result of our World Campus activities which we will address later in the report.

[Meet our patient advocates](#)

Our patient advocates are highly educated, well informed and very eloquent. In their work they combine emotion (as a driving force) with their background based on science, knowledge and facts. They are visible in dozens of initiatives, give dozens of talks and write dozens of blogs, articles and books. Our Patient Advocates are themselves cancer patients or have experienced the devastation of personal and family life that is caused by cancer. They have felt the anguish and the suffering. We take cancer personally.

Inspire2Live is highly recognized in initiatives around personalized medicine, setting up innovative research for better treatments, concentration of cancer care in excellent cancer centres, better diagnosis, food and cancer, prevention (among this is tobacco), the affordability and access to drugs, the design of trials, influencing government and industry... We know what we are talking about. Some of these topics are being discussed in parliament. Through lobbying we find effective and efficient access to the members of parliament in The Hague and Brussels... We know how important it is to influence.

Through our activities in the World Campus, we work towards a strategic alliance with the International Agency of Research on Cancer of the World Health Organisation (IARC). We know how to cooperate and already have an intense relationship with WHO/IARC.

Meetings

We had, just as in 2022, lots of online meetings and of course these meetings were global.

The regular [World Campus Meeting](#) every last Wednesday of the month at 3 pm CET with all our patient advocates is a huge success and very well visited. The structure is:

- Start with a short introduction of the new patient advocates
- A lecture by a guest speaker or by one of our patients advocates
- Followed by an extended discussion on this topic

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Updates from the working groups

We introduced a new topic in the sessions: 'Can you help me?' In this topic we discuss the activities that our members perform and help them with answers to their questions and solve their problems where we can. A brilliant way of reciprocity and altruism. This idea started at our Annual Congress November 29, 30 and December 1, 2023.

Our working groups

Out of the 'Last Wednesday of the month' meetings, as well out of our Annual Congress, arise ideas and initiatives. We see that the flow 'idea - initiative – project – going concern' has now been established in Inspire2Live and her daughter company SanInfo.

When our advocates think that an idea is fruitful and can add value to our mission, a working group is started. We now have the following working groups:

- Access to Medicines and Personalized Medicine
- The Book project
- Breast Cancer
- Data
- Lifestyle
- Multi Cancer Early Detection (MCED)
- Pain and Palliative Care
- Registries

Communication

We have added our new [heroes of cancer](#) to our website and a wrap up of our Annual Congress 2023.

During our annual congress the Communication Team worked together with a great group of people for maximum exposure on our website and social media channels. A lot of preparation time went into this. After the congress all talks and presentations have been published on our website. Additional video material is available and will be used for promotion. We thank all our partners for supporting us during the congress.

On a regular basis we publish articles on our website and promote it on our social media channels (Facebook, Instagram, LinkedIn, X). We also have been working on a series of podcasts and collaborating on the book project.

Each time a patient advocate joins our organisation we publish their bio on our website. We also add them to our MS Teams environment.

Our MS Office 365 environment is donated for free by Microsoft and is maintained by our Communication Team.

We are thankful for the free support of [DTX](#), a small organisation who kindly assist us in technical Microsoft365 matters.

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Our achievements

Inspire2Live was founded in 2010 and started immediately after the Annual congress of 2011 with her activities. We are very proud of the many things we have achieved.

We started initiatives for organoids, in the Netherlands we created for cancer patients the possibility to have their Whole Genome Sequenced through a unanimous majority in the Dutch Parliament (it works as an example and catalyst for other countries).

What about starting the World Campus; a network of more than 100 patient advocates in more than 40 countries working together to fight cancer and cooperate based on reciprocity. The principles of the Red Cross have been implemented by Inspire2Live. Political, religious, historical or cultural differences are not allowed to stand in the way of cooperation. In this network researchers from Iran work with researchers from Israel. Turkey is facilitating Armenia. The World Campus as a global advocacy group for cancer has no precedent.

Much more has been [achieved](#) and you find the descriptions on our website.

Our Projects

Inspire2Live has many working groups as described above. Out of these activities come a lot of projects. Our advocates work intensely on this with the aim to improve the quality of life of cancer patients and their loved ones globally.

We started a registry for cancer in Armenia! And we have designed a project that is the first of its kind as a real patient centric approach for treating patients: DEEP Diagnostics (for this patient, with her specific defect, at this moment, we need this personalised treatment). Away from drug centric and now real Personalized Medicine.

We have built a close relation and cooperation with [SeekIn](#), the Chinese/American company of our own patient advocate [Mao Mao](#). We (Inspire2Live and SeekIn) have products on the shelf, not only in research, that can detect cancer in its earliest stage and can also determine after 1 cycle whether a treatment works or not. These are unique products that we bring to all the people in the world.

Many more [projects](#) have been started and you find them on our website.

Statement from the Finance Manager

You will find our financial position at the end of this document.

In Memoriam

We enthusiastically announce that this year we have not lost a patient advocate. This is a unique year, and we express our hope that 2024 will be a year like this.

Amsterdam, March 28, 2024

Foundation Inspire2Live

Board members Ilona Schelle, Peter Kapitein & Tielo Jongmans

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Foundation Inspire2Live

Financial Report 2023

Balance sheet as at 31 December 2023

		2023	2022
		EUR	EUR
Fixed assets			
Participations	1	1	1
Long-term receivables	2	<u>13,000</u>	<u>10,000</u>
Total fixed assets		13,001	10,001
Current assets			
Receivables	3	17,798	99
Cash and cash equivalents	4	<u>44,030</u>	<u>62,832</u>
Total current assets		74,829	72,932
Foundation's equity	5	25,583	20,697
Current liabilities	6	<u>49,246</u>	<u>52,235</u>
		<u>74,829</u>	<u>72,932</u>

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Statement of income and expenses for the year ended 31 December 2023

		2023	2022
		EUR	EUR
Income	7	127,368	879
Operating costs	8	<u>122,383</u>	<u>164,585</u>
Result		4,985	-/- 163,706
Share in result of group companies		<u>-/- 99</u>	<u>0</u>
Total result		4,886	-/- 163,706

Notes to the financial statements for the year 2023

General

Applied standards

The financial statements were prepared in accordance with good merchant use and the provisions of Part 9, Book 2, of the Netherlands Civil Code. Inspire2Live however uses its own principles for valuation and determination of results, as allowed by Dutch law. These principles, however, largely correspond to the Guidelines for Annual Reporting for small organisations with no profit motive (RJ(k)-C1).

Activities

The principal goals of Inspire2Live are:

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



- stimulating organisations that aim to organize events for cancer research
- setting up global collaboration to achieve medical research in a sustainable manner
- promoting and supporting scientific research into cancer in all possible forms, so that people can live a happy, healthy life in harmony with cancer and getting cancer under control
- to profile her behaviour both internally and externally as a non-governmental organisation ("NGO") and in the performance of her duties
- maintain independence

The foundation intends to achieve its goal by, among other things:

- promoting patient advocacy and supporting research.
- the development of activities that contribute directly or indirectly to the achievement of its objective, including ancillary commercial and profitable activities within the limits of what is legal permitted and the proceeds of which will become available at any time and are intended for achieving the objective.

Principles for the valuation of assets and liabilities and the determination of the results

General

If not stated otherwise, assets and liabilities are shown at nominal value.

An asset is disclosed in the balance sheet when it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the cost of the asset can be reliably measured. A liability is disclosed in the balance sheet when it is expected to result in an outflow from the entity of resources embodying economic benefits and the amount of the obligation can be measured with sufficient reliability.

If a transaction results in a transfer of future economic benefits and or when all risks relating to assets or liabilities transfer to a third party, the asset or liability is no longer included in the balance sheet. Assets and liabilities are not included in the balance sheet if economic benefits are not probable or cannot be measured with sufficient reliability.

The income and expenses are accounted for in the period to which they relate.

The preparation of the financial statements requires the board to form opinions and to make estimates and assumptions that influence the application of principles and the reported values of assets and liabilities and of income and expenditure. The actual results may differ from these estimates. The estimates and the underlying assumptions are constantly assessed. Revisions of estimates are recognized in the period in which the estimate is revised and in future periods for which the revision has consequences.

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Receivables

Receivables are stated at nominal value less a provision for doubtful debts. Provisions are designated on the basis of individual assessment of recoverability of the receivable.

Result

The result is calculated as the difference between income and all the costs attributable to it during the year under review. The costs are calculated with due regard for the applicable valuation principles stated previously.

Balance sheet as at 31 December 2023

Financial fixed assets

1. Participations	2023	2022
	EUR	EUR
Participation SanInfo B.V.	1	1

2. Long term receivables	2023	2022
	EUR	EUR
Loan SanInfo B.V.	10,000	10,000
Loan Franklin Mtei	<u>3,000</u>	<u>0</u>
31 December	<u>13,000</u>	<u>10,000</u>

In 2020 Inspire2Live financed the start-up capital of Inspire2Go BV. Inspire2Go's main objective is to provide care projects and tasks commercially, with the proceeds ultimately benefiting causes such as Inspire2Live. The loan of € 10,000 can be seen as risk-bearing capital. For the time being, no interest is due on the outstanding balance. Inspire2Go has been succeeded by SanInfo, and all its assets and obligations are now part of SanInfo, which is a wholly owned subsidiary of Inspire2Live.

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



Current assets

3. Receivables	2023	2022
	EUR	EUR
Current account SanInfo B.V.	0	99
Debtors	5,352	0
Other receivables	<u>12,446</u>	<u>0</u>
31 December	<u>17,798</u>	<u>99</u>

4. Cash and cash equivalents	2023	2022
	EUR	EUR
Rabobank 1356.22.883	24,046	12,832
Rabobank savings account	<u>19,984</u>	<u>50,000</u>
31 December	<u>44,030</u>	<u>62,832</u>

5. Foundation's equity	2023	2022
	EUR	EUR
Balance as at 1 January	20,697	184,403
Result for the year	<u>4,886</u>	<u>-/- 163,706</u>
31 December	<u>25,583</u>	<u>20,697</u>

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



6. Current liabilities	2023	2022
	EUR	EUR
Creditors	49,088	52,214
Other liabilities	<u>158</u>	<u>21</u>
31 December	<u>49,246</u>	<u>52,235</u>

Statement of income and expenses for the year ended 31 December 2023

7. Income	2023	2022
	EUR	EUR
Total	<u>127,368</u>	<u>879</u>

During the 2023 financial year, the average number of employees, converted into full-time equivalents on the payroll of the foundation, amounted to nil persons (2022: nil persons).

The board of Foundation Inspire2Live does not receive any remuneration and is independent of any scientific or fundraising organisation from which the foundation receives subsidy or other grants. De Nederlandsche Bank allows Peter Kapitein to work three days a week for the foundation.

8. Operating costs	2023	2022
	EUR	EUR
Volunteer allowances	0	0
General costs	9,500	49,999
Project costs	112,081	114,000
Financial costs	<u>802</u>	<u>586</u>
	<u>122,383</u>	<u>164,585</u>

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org



9. General costs	2023	2022
	EUR	EUR
Travel costs for connection	435	7,599
Costs Inspire2Go	0	167
External hiring	0	10,000
Various costs	<u>9,065</u>	<u>0</u>
	<u>9,500</u>	<u>49,999</u>

The travel costs for connection consist of travel expenses for submitted km-declarations.

10. Project costs	2023	2022
	EUR	EUR
Annual congress	104,141	79,013
May Assembly	0	29,987
Costs Kenya en Tanzania trip	6,469	0
Costs MCED	1,351	0
Fundraising costs	120	0
Project Lead World Campus	<u>0</u>	<u>5,000</u>
	<u>112,081</u>	<u>114,000</u>

Operating costs include VAT, which cannot be refunded by Foundation Inspire2Live.

Inspire2Live agreed that charges for temporary staff will not exceed EUR 80 per hour. In 2023 no payments have been made to staff members.

Amsterdam, March 28, 2024

Foundation Inspire2Live

Board members Ilona Schelle, Peter Kapitein & Tielo Jongmans

We are the patient's voice in cancer!

If about us, not without us • www.inspire2live.org